GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...
Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable futur ...
9d
Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...
The FDA issued a complete response letter for the BLA submission of subcutaneous amivantamab for EGFR-mutated NSCLC, citing ...
or placebo administered concurrently with both sequential regimens of paclitaxel (80 mg/m 2 IV weekly) for 12 weeks plus carboplatin (AUC of 5 IV for 4 doses) followed by investigator’s choice of ...
OVATION 2 evaluated the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (NACT) of paclitaxel ...
Key eligibility criteria were stage III-IV lung cancer (small cell lung cancer and non–small cell lung cancer), Eastern Cooperative Oncology Group performance status ≤2, and no sign of disease ...
Washington, DC: The Executive Board of the International Monetary Fund (IMF) concluded the Article IV consultation[1] with Kuwait. The economy remains in recession due to OPEC+ production cuts, but a ...
The HARMONICâ„¢ trial is evaluating LP-300 in combination with carboplatin and pemetrexed in never-smoker NSCLC patients that have relapsed following treatment with TKIs. Dr. Reggie Ewesuedo, VP of ...
Spirit of Tasmania IV has departed its shipbuilder's port in Finland and is making its way to Leith port in Edinburgh, Scotland. In a report released in October, Tasmania's Department of State ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback